{"id":"tmc435","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL501849","moleculeType":"Small molecule","molecularWeight":"749.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TMC435 works by inhibiting the protease enzyme, which is essential for the replication of the HIV-1 virus. This inhibition prevents the virus from producing new viral particles, thereby reducing the viral load in the body.","oneSentence":"TMC435 is a protease inhibitor used to treat HIV-1 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02824315","phase":"PHASE1","title":"Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05","conditions":"Healthy","enrollment":22},{"nctId":"NCT03099135","phase":"PHASE3","title":"A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-10","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT02945020","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT02455167","phase":"PHASE3","title":"Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-05","conditions":"Hepatitis C","enrollment":9},{"nctId":"NCT02404805","phase":"NA","title":"Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-02","conditions":"HIV, Hepatitis C","enrollment":25},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT04385407","phase":"PHASE2","title":"Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-04","conditions":"Chronic Hepatitis C Virus Infection","enrollment":203},{"nctId":"NCT02765490","phase":"PHASE2","title":"Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-09","conditions":"Hepatitis C, Chronic","enrollment":365},{"nctId":"NCT02512562","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2015-07-31","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT02993250","phase":"PHASE2","title":"A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2016-12-21","conditions":"Hepatitis C, Chronic","enrollment":33},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02569710","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2015-10-31","conditions":"Chronic Hepatitis C","enrollment":161},{"nctId":"NCT02206932","phase":"PHASE4","title":"A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2014-08","conditions":"Hepatitis C, Chronic, HIV CDC Category A1","enrollment":""},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02421211","phase":"PHASE2","title":"A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-05-19","conditions":"Hepatitis C, Chronic","enrollment":41},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT02214420","phase":"PHASE4","title":"SMV + SOF With/Without RBV for IFN-II Patients With CHC","status":"COMPLETED","sponsor":"SC Liver Research Consortium, LLC","startDate":"2014-10","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT03059303","phase":"PHASE1","title":"Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT03155893","phase":"PHASE1","title":"A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-05-12","conditions":"Healthy","enrollment":59},{"nctId":"NCT03277755","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2017-09-11","conditions":"Hepatic Impairment","enrollment":""},{"nctId":"NCT02385071","phase":"PHASE1","title":"A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-04-28","conditions":"Healthy","enrollment":48},{"nctId":"NCT02628717","phase":"","title":"Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":558},{"nctId":"NCT02624063","phase":"PHASE4","title":"Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT01567735","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-03-27","conditions":"Hepatitis C","enrollment":107},{"nctId":"NCT02932293","phase":"PHASE2","title":"Triple Combination DAAs for Treating HCV GT1b Subjects","status":"WITHDRAWN","sponsor":"Humanity and Health Research Centre","startDate":"2016-12","conditions":"Chronic Hepatitis C Infection","enrollment":""},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT01349465","phase":"PHASE3","title":"3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-07-04","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT02268864","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2015-01","conditions":"Hepatitis C, Chronic","enrollment":106},{"nctId":"NCT03069001","phase":"PHASE4","title":"Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-06","conditions":"HCV","enrollment":90},{"nctId":"NCT02349048","phase":"PHASE2","title":"Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Hepatitis C Virus","enrollment":68},{"nctId":"NCT01628692","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus","enrollment":230},{"nctId":"NCT02885454","phase":"PHASE1","title":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02118597","phase":"","title":"An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Hepatitis C, Chronic","enrollment":19},{"nctId":"NCT02250807","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-01","conditions":"Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02165189","phase":"PHASE2","title":"An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2014-08","conditions":"Hepatitits C","enrollment":46},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02278419","phase":"PHASE2","title":"An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2014-12","conditions":"Hepatitis C","enrollment":63},{"nctId":"NCT02485080","phase":"PHASE4","title":"Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2015-09","conditions":"PT-NANBH","enrollment":""},{"nctId":"NCT01846832","phase":"PHASE3","title":"A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-09","conditions":"Hepatitis C, Chronic, Infection","enrollment":232},{"nctId":"NCT02771405","phase":"PHASE3","title":"Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02531269","phase":"","title":"Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT01485991","phase":"PHASE3","title":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-02","conditions":"Hepatitis C","enrollment":771},{"nctId":"NCT02114177","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":310},{"nctId":"NCT01323244","phase":"PHASE3","title":"A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-12","conditions":"Hepatitis C","enrollment":142},{"nctId":"NCT02114151","phase":"PHASE3","title":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":103},{"nctId":"NCT02168361","phase":"PHASE4","title":"The SIM-SOF Trial for Hepatitis C","status":"COMPLETED","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2013-12","conditions":"Chronic Hepatitis C","enrollment":93},{"nctId":"NCT02702739","phase":"PHASE4","title":"Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Camillo Forlanini","startDate":"2015-01","conditions":"Liver Cirrhosis","enrollment":270},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02253550","phase":"PHASE2","title":"Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Peter J. Ruane, M.D.","startDate":"2014-10","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT02103699","phase":"","title":"A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2014-02","conditions":"Hepatitis C Virus","enrollment":315},{"nctId":"NCT01907724","phase":"PHASE1","title":"Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05","conditions":"Hepatitis C, Chronic","enrollment":34},{"nctId":"NCT01813513","phase":"PHASE1","title":"Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01","conditions":"Chronic Hepatitis C Infection","enrollment":42},{"nctId":"NCT01724086","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":90},{"nctId":"NCT01725529","phase":"PHASE3","title":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":457},{"nctId":"NCT02397395","phase":"PHASE2","title":"An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.","status":"WITHDRAWN","sponsor":"Janssen R&D Ireland","startDate":"2015-05","conditions":"Renal Impairment, End-stage Renal Disease","enrollment":""},{"nctId":"NCT02485262","phase":"","title":"Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience","status":"UNKNOWN","sponsor":"Arrowhead Regional Medical Center","startDate":"2013-11","conditions":"Hepatitis C","enrollment":340},{"nctId":"NCT01852604","phase":"PHASE2","title":"Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03","conditions":"Chronic Hepatitis C Virus","enrollment":143},{"nctId":"NCT01466790","phase":"PHASE2","title":"A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-01","conditions":"Hepatitis C","enrollment":168},{"nctId":"NCT01479868","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-10","conditions":"Hepatitis C Virus Genotype-1","enrollment":109},{"nctId":"NCT02071355","phase":"PHASE1","title":"A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT00812331","phase":"PHASE2","title":"A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-03","conditions":"Hepatitis C","enrollment":37},{"nctId":"NCT02018536","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT02064842","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2014-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT01224197","phase":"PHASE1","title":"TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-10","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01366638","phase":"PHASE3","title":"A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-05","conditions":"Hepatitis C, Chronic","enrollment":79},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT00996476","phase":"PHASE2","title":"A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2009-07","conditions":"Hepatitis C, Chronic","enrollment":92},{"nctId":"NCT01707342","phase":"PHASE1","title":"A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Healthy Male Participants","enrollment":6},{"nctId":"NCT01290731","phase":"PHASE3","title":"A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":49},{"nctId":"NCT01288209","phase":"PHASE3","title":"A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":106},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT00915564","phase":"PHASE1","title":"A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-09","conditions":"Hepatitis C","enrollment":13},{"nctId":"NCT01046058","phase":"PHASE1","title":"TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-01","conditions":"Hepatitis C Virus","enrollment":23},{"nctId":"NCT01381835","phase":"PHASE1","title":"TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-07","conditions":"Hepatitis C Virus","enrollment":16},{"nctId":"NCT01891851","phase":"PHASE1","title":"A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2007-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT01571570","phase":"PHASE1","title":"A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-03","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT01124799","phase":"PHASE1","title":"TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-07","conditions":"Hepatitis C Virus","enrollment":49},{"nctId":"NCT01269294","phase":"PHASE1","title":"TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-01","conditions":"Hepatitis C","enrollment":60},{"nctId":"NCT01799603","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT00741169","phase":"PHASE1","title":"TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-06","conditions":"Hepatitis C, HCV, Tuberculosis","enrollment":21},{"nctId":"NCT01134718","phase":"PHASE1","title":"TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-06","conditions":"Hepatitis C Virus","enrollment":24},{"nctId":"NCT01090700","phase":"PHASE1","title":"TMC435-TiDP16-C112 - Interaction Trial With Antidepressants","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-05","conditions":"Hepatitis C Virus","enrollment":20},{"nctId":"NCT01689623","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT01202825","phase":"PHASE1","title":"TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-04","conditions":"Hepatitis C","enrollment":72},{"nctId":"NCT01486004","phase":"PHASE1","title":"A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-11","conditions":"Hepatitis C Virus","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TMC 435","G008"],"phase":"phase_3","status":"active","brandName":"TMC435","genericName":"TMC435","companyName":"Tibotec Pharmaceuticals, Ireland","companyId":"tibotec-pharmaceuticals-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMC435 is a protease inhibitor used to treat HIV-1 infection. Used for Treatment of HIV-1 infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}